$XBI $103.89 0.73% %
Covid Updates
$TNXP +1.7% Tonix Pharmaceuticals Initiates Enrollment in Clinical Trial of TNX-2100, a Diagnostic Skin Test to Measure Functional T Cell Immunity to SARS-CoV-2 source
Pipeline Updates
$GKOS +10.6% Glaukos’ iDose®TR Demonstrates Sustained IOP Reduction and Favorable Safety Profile Over 36 Months in Phase 2b Study source
$GKOS +10.6% Glaukos Announces First Patient Enrolled in Phase 2 Clinical Trial for Dry Eye Disease source
$GKOS +10.6% Glaukos Announces First Patient Enrolled in Phase 2 Clinical Trial for Presbyopia source
$XNCR -0.9% Xencor Highlights 2022 Corporate Priorities and Portfolio Milestones source
$MIRM +2.7% Mirum Pharmaceuticals Provides Business Update and Highlights Key 2022 Corporate Milestones source
$PLRX +11.1% Pliant Therapeutics Highlights Recent Developments for Lead Program PLN-74809 and Expected 2022 Milestones source
$ALDX -0.8% Aldeyra Therapeutics Announces Positive Top-Line Data from Phase 2 Dry Eye Chamber Clinical Trial of Reproxalap, an Investigational New Drug, Compared to Xiidra® source
$HARP +4.4% HARPOON THERAPEUTICS PROVIDES PIPELINE DEVELOPMENT MILESTONES FOR 2022 source
$AGTC +5.2% AGTC Exceeds Enrollment Target in SKYLINE Trial of AGTC-501 for the Treatment of X-linked Retinitis Pigmentosa (XLRP) source
$ONCY +5.3% Oncolytics Biotech® Releases a Letter to Shareholders - 2021 Review and 2022 Outlook source
$VSTM +1.1% Verastem Oncology Outlines Key 2022 Strategic Priorities and Upcoming Catalysts for Advancing VS-6766 as a Backbone of Therapy for RAS Pathway-Driven Cancers source
$RCKT +2.6% Rocket Pharmaceuticals Highlights Anticipated 2022 Milestones Across Lentiviral and AAV Gene Therapy Clinical Programs source
$BDTX +13.3% Black Diamond Therapeutics Announces FDA Allowance of IND Application for BDTX-1535, A MasterKey Inhibitor of EGFR for the Treatment of Gliobastoma and Non-Small Cell Lung Cancer source
Business Updates
$
Posted by JM
Comments